dc.description.abstract | Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59(34.3%), preemptive for 20(11.6%), and therapeutic for 93(54.1%). For the prophylactic group, the median number of DLIs was 1 (IQR:1-2.5) with a median first dose of 0.1 x 10(6) CD3+ T cell/kg, for the preemptive 2 (IQR:1-3) with 0.5 x 10(6) CD3+ T cell/kg, for the therapeutic 1 (IQR:1-3) with 1 x 10(6)CD3+ Tcell/kg, respectively. OS after first DLI was 61% (46-75%) for prophylactic, 40% (19-61%) for preemptive, and 22% (13-31%) for therapeutic. CI of II-IV aGVHD and cGVHD was 17%(7-27%) and 53% (40-67%) for the prophylactic, 20% (2-38%) and 21% (3-39%) for the preemptive, 17% (9-24%) and 24% (15-33%) for the therapeutic group, respectively. Our data show great variability in the indications and modalities of DLI across responding EBMT centers. Survival rates remain relatively low in patients with active disease. While the cumulative incidence of aGVHD appears acceptable, we showed a high incidence proportion of cGVHD in the prophylactic group, compared with preemptive and therapeutic DLI. These data should be investigated further in prospective clinical trials. | en_US |
dc.department-temp | [Santoro, Nicole; Di Ianni, Mauro] Osped Civile Santo Spirito, Dept Hematol & Oncol, Pescara, Italy; [Mooyaart, Jarl E.] EBMT Stat Unit, Leiden, Netherlands; [Devillier, Raynier] Univ Aix Marseille, Inst Paoli Calmettes, Ctr Lutte Canc, Inserm UMR 1068, Marseille, France; [Devillier, Raynier] Univ Aix Marseille, Ctr Rech Cancerol Marseille CRCM, Inserm UMR 1068, Marseille, France; [Koc, Yener] Medicana Int Hosp Istanbul, Istanbul, Turkey; [Vydra, Jan] Inst Hematol & Blood Transfus, Prague, Czech Republic; [Castagna, Luca] Ist Clin Humanitas, Milan, Italy; [Gulbas, Zafer] Anadolu Med Ctr Hosp, Kocaeli, Turkey; [Diez Martin, Jose] Univ Complutense, Serv Hematol, Hosp G Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon,Dept Med, Madrid, Spain; [Araujo, Mercedes Colorado] Hosp U Marques Valdecilla, Santander, Spain; [Kulagin, Alexander] Pavlov Univ, RM Gorbacheva Res Inst, St Petersburg, Russia; [Arat, Mutlu] Demiroglu Bilim Univ, Istanbul Florence Nightingale Hosp Istanbul, Istanbul, Turkey; [Herrera Arroyo, Concepcion] Univ Cordoba, IMIBIC, Hosp Univ Reina Sofia, Cordoba, Spain; [Martelli, Maria Paola] Univ Perugia, Ctr Ric Ematooncol, Inst Hematol, Osped S Maria Misericordia, Perugia, Italy; [Hoogenboom, Jorinde D.] EBMT Leiden Study Unit, Leiden, Netherlands; [de Wreede, Liesbeth C.] Leiden Univ Med Ctr, Leiden, Neth | en_US |